Last update Dec. 30, 2022
It is an aminobisphosphonate that, like other bisphosphonates, inhibits bone resorption. It is used to treat severe hypercalcemia and osteolytic bone lesions associated with malignant neoplasms and in the prevention and treatment of postmenopausal osteoporosis. It is administered by slow intravenous infusion every day or every 3 to 4 weeks depending on the disease.
A latest update no published data were found on excretion in the breast milk.
Most bisphosphonates are acidic compounds that achieve low plasma concentration. Both features make it unlikely excretion into the milk in clinically significant amount.
Intestinal absorption of bisphosphonates is very low even during fasting and is considered negligible in the presence of milk due to formation with the calcium of non absorbable compounds.
Among bisphosponate preparations, Tiludronate and Zoledronate have the longest half-lives period of elimination and thus they are the less indicated to take while breastfeeding.
Until more data about this drug regarding breastfeeding is available, safer known alternatives (pamidronate) should be of choice, especially in the neonatal period and in case of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM